{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.5","value":"-0.5"},{"groupId":"OG001","spread":"2.6","value":"-0.1"}]}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.8","value":"-0.9"},{"groupId":"OG001","spread":"2.8","value":"-0.4"}]}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9","value":"-1.5"},{"groupId":"OG001","spread":"3.3","value":"-0.8"}]}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.2","value":"-1.8"},{"groupId":"OG001","spread":"3.5","value":"-1.1"}]}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.3","value":"-2.1"},{"groupId":"OG001","spread":"3.9","value":"-1.2"}]}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.8","value":"-2.0"},{"groupId":"OG001","spread":"4.6","value":"-1.2"}]}],"title":"Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.3","value":"-2.2"},{"groupId":"OG001","spread":"5.0","value":"-1.4"}]}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"515"},{"groupId":"OG001","value":"518"}],"units":"Participants"}],"description":"The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The intent-to-treat (ITT) population includes all participants who were randomized with data at baseline and at each timepoint. Missing values were imputed using Last Observation Carried Forward.","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 11, 15, 22, and 29","title":"Change in National Early Warning Score (NEWS) From Baseline","type":"SECONDARY","unitOfMeasure":"units on a scale"}